Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ABT terminates icatibant license

Kos, a subsidiary of Abbott (ABT), terminated an agreement that gave it North American

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE